Ocugen (OCGN) Q4 2022 Earnings Call Transcript

Ocugen (OCGN)
Q4 2022 Earnings Call
Feb 28, 2023, 8:30 a.m. ET

Contents:

• Prepared Remarks
• Questions and Answers
• Call Participants

Prepared Remarks:

Operator

Good morning, and welcome to Ocugen's fourth quarter and full year 2022 financial results and business update call. Please note that this call is being recorded at this time. All participant lines are in a listen-only mode. Following the speakers commentary, there will be a question-and-answer session.

I will now turn the call over to Tiffany Hamilton, Ocugen's head of corporate communications. You may begin.

Tiffany Hamilton -- Head of Corporate Communications

Thank you. Joining me today are Ocugen's chairman, CEO, and co-founder, Dr. Shankar Musunuri, who will provide a business update; and our chief accounting officer and senior vice president of finance, Jessica Crespo, who will provide more detail on our financial results. Earlier this morning, we issued a press release detailing business and operational highlights for the fourth quarter and full year of 2022.

We encourage listeners to review this press release, which is available on our website at ocugen.com. This call is being recorded. And a replay of the accompanying slide presentation will be available on the investors section of the Ocugen website for approximately 45 days. This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties.

We may, in some cases, use terms such as predict, believe, potential, proposed, continue, estimate, anticipate, expect, plans, intend, may, could, might, will, should, or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties and may cause actual events or results to differ materially from our current expectations. Investors should familiarize themselves with the company's filings for complete details. Except as required by law, we assume no obligation to update forward-looking statements contained in this presentation, whether as a result of new information, future events, or otherwise after the date of this presentation.

Finally, Ocugen's 10-K covering 2022 will be filed soon after today's call. I will now turn the call to Dr. Musunuri.

Shankar Musunuri -- Chairman and Chief Executive Officer

Thank you, Tiffany. Good morning, and thank you all for joining us today. I'm excited to share with you the significant progress Ocugen made in 2022 and during the first two months of 2023 to further advance our diversified pipeline, while continuously focusing on patients and pursuing courageous innovation. Fueled by our team's passion, dedication, and visionary mindset, we witnessed progress across all our clinical programs.

I will also provide more on our objectives for 2023, leading into 2024. Let me commence with an update on our gene therapy program. In December 2022, we announced that OCU400, our investigational drug candidate for the treatment of retinitis pigmentosa and Leber congenital amaurosis, was granted expanded orphan drug designation by the U.S. FDA, which supports the therapeutic potential of OCU400 to treat multiple inherited retinal diseases, the single.

OCU400 is symbolic of Ocugen's gene modifier approach that is based on nuclear hormone receptors that regulate diverse physiological functions in the retina, such as development, metabolism, cellular functions, and thereby establishes homeostasis to potentially restore retinal health and function. In the U.S., RP and LCA affect 110,000 and 15,000 thousand people, respectively. And globally, these conditions affect approximately 1.6 million people. And despite its prevalence, RP and LCA patients have limited treatment options.

As current approved or in-development gene therapies focus on individual genes, OCU400 addresses shortcomings of current gene therapy approaches as a broad spectrum gene-agnostic approach to genetically diverse inherited retinal diseases. We have completed enrollment of our RP patients in the phase 1/2 trial protocol and continue to enroll patients with LCA. We also established the high dose to be the maximum tolerable dose. We plan to start the phase 3 clinical trial near the end of 2023.

OCU200, our biologic product candidate, is a recombinant fusion protein consists of two human proteins, tumstatin and transferrin, and is designed to treat severely sight-threatening diseases, like diabetic macular edema, diabetic retinopathy, and wet AMD. Millions of patients worldwide are affected by these conditions. However, current therapies target only one pathway, either angiogenesis or inflammation, and up to 50% of patient populations experience limited or no response to current treatments. OCU200 works with a distinct mechanism of action compared to existing therapies and targets multiple causative pathways, such as angiogenesis, oxidation, and inflammation, and has the potential to offer better treatment on patients.

Yesterday, we submitted an investigational new drug application, IND, at the U.S. Food and Drug Administration to initiate a phase 1 clinical trial of OCU200 for treating diabetic macular edema, DME. This regulatory milestone fulfills the company's commitment to file the IND for OCU200 within the first quarter of 2023. We are proud to further advance OCU200, one of Ocugen's founding ophthalmic programs.

Another major highlight in 2022 we'd like to note is the expansion of our pipeline into cell therapy with NeoCart, a phase 3 ready regenerative cell therapy technology that combines evolutionary advancement in bioengineering and cell processing to enhance the autologous cartilage repair process. We are developing NeoCart specifically for the treatment of articular cartilage defects in the knee. Current therapies to treat cartilage damage in the knee are suboptimal with varying outcomes due to variable cellular responses. The current standard of care suffers from factors, such as pain, reduced knee function, failure to address cartilage damage, donor tissue availability, and open surgery.

In addition to receiving regenerative medicine advanced therapy designation from the FDA, we received a concurrence from the FDA on the confirmatory phase 3 clinical trial design. We have already begun renovating our facility to accommodate cGMP manufacturing for clinical trials, and we are planning to initiate phase 3 randomized controlled study and subjects with articular cartilage defects in the first half of 2024. Now, turning to our vaccines portfolio and continued efforts to significantly mitigate the spread of COVID-19. From a public health perspective, we actively monitor the medical need for a more durable vaccine, as more than a million cases of COVID-19 were diagnosed in the U.S.

over the last 30 days. The International Health Regulations Emergency Committee of the World Health Organization recently held a meeting in January this year to discuss the state of the COVID-19 pandemic, which revealed that the global risk of COVID-19 and its ongoing transmission as high. This assessment was based on factors regarding circulating SARS-CoV-2 variants of concern, status of global vaccination, and hybrid immunity, and unexpected and relatively early seasonal return of the flu, which further encumbers already constrained healthcare systems. The data back this up.

More than 5 million cases were diagnosed, and nearly 40,000 people died worldwide in the last 28 days. Current COVID-19 vaccines are limited by a lack of durability and inability to stop transmission. As part of our commitment to address current gaps and the fight against COVID-19, we are developing a novel mucosal vaccine platform that includes OCU500; a bivalent COVID-19 inhale vaccine; OCU510, a seasonal quadrivalent flu inhaled vaccine; and OCU520, a combination quadrivalent seasonal flu and bivalent COVID-19 inhaled vaccine. The 500 series is based on a novel chat platform designed to reduce transmission and protect against new variants.

The OCU500 series is designed for annual boosters. For the 2022 to '23 flu season or 50% of the U.S. population, about six months of age, received a seasonal flu shot, representing a market size of more than 170 million doses. The OCU400 series of vaccines and the development brands Ocugen a distinct product candidate profile status that could significantly impact major global health obstacles and maximize their opportunity to sow broader patient markets.

Regarding our injectable COVID-19 vaccine already in development, COVAXIN, we successfully completed enrollment for our COVAXIN phase 2/3 immuno-bridging and broadening clinical trial in December 2022 and reported top-line data in January 2023. This data showed that the vaccine was well tolerated and demonstrated immunogenicity. We plan to present final data and analysis at midyear. At the beginning of November 2022, we held Ocugen's first R&D day since the company's inception to showcase our dynamic pipeline and world-class team to investors, analysts, [Inaudible], and other key stakeholders of the company.

During that meeting, we shared the long-term outlook for the company. On this call, I would like to spend some more time recapping our key priorities over the next 12 to 18 months. First, our gene therapy programs. We're anticipating OCU400 preliminary efficacy data midyear and plan to start the phase 3 clinical trial near the end of the year.

For OCU410, we are on track to submit INDs to the FDA in the second quarter of 2023 to initiate phase 1/2 trials for dry AMD and Stargardt disease. With OCU410, we believe we have a potential onetime curative therapy with a single injection. Dry AMD affects vision in 10 million people in the U.S. and over 266 million people worldwide.

Also targeting severe IDCs, we look forward to the initiation of our OCU200 phase 1 clinical trial with the preliminary data anticipated in the fourth quarter of this year. We plan to complete the cGMP facility construction and the manufacturing of NeoCart in the fourth quarter in support of initiating a phase 3 clinical trial in the first half of 2024. For our inhaled vaccine series, we are planning to file an IND to initiate clinical trials in the fourth quarter of 2024. One overarching and imminent objective for Ocugen is to identify synergies and partnership with organizations that can help drive the development of our comprehensive pipeline.

With that, I'm thrilled about the recent appointment of our new chief business officer, Quan Vu, who is a seasoned healthcare business executive with more than two decades of experience in business development, strategy, and finance. We look forward to benefiting from the prospects of Quan's leadership and, together, further evolve as a fully integrated, patient-centric biotech company. Our strategic initiative to identify partnership for our programs is also critical for our operational objective to [Inaudible] capital and extend runway as appropriate. With that, I will now turn the call over to our chief accounting officer, senior vice president of finance, Jessica Crespo, to review our Q4 and 2022 financial metrics.

Jess?

Jess Crespo -- Chief Accounting Officer and Senior Vice President of Finance

Thank you, Shankar, and good morning, everyone. I will now provide a brief overview of our key financial results for the fourth quarter and full year 2022. Our research and development expenses for the quarter ended December 31, 2022, were $17.2 million compared to $7.1 million for the fourth quarter of 2021. For the full year ended December 31, 2022, research and development expense was $49.8 million compared to $35.1 million for the year ended December 31, 2021, with the increase primarily driven by the advancement of our product candidates into clinical trials.

General and administrative expenses for the fourth quarter ended December 31, 2022, were $6.9 million compared to $7.5 million for the fourth quarter of 2021. General and administrative expenses for the full year 2022 were $35.1 million compared to $22.9 million for the year ended December 31, 2021. Net loss was approximately $21.9 million, or $0.10 net loss per common share, for the quarter ended 2022 Q4 compared to a net loss of approximately $14.6 million or $0.07 net loss per share for the fourth quarter of 2021. Full year net loss was $81.4 million, or $0.38 net loss per share, compared to a net loss of $58.4 million for the full year of 2021, or $0.30 net loss per share.

Our cash, cash equivalents, and investments totaled $90.9 million as of December 31, 2022, compared to $95.1 million as of the year ended December 31, 2021. We expect that our cash, cash equivalents, and investment balance will enable us to fund operations into the first quarter of 2024. We're continuously exploring opportunities to increase our working capital, and we'll be focused on seeking out partnerships and nondilutive funding, as Shankar mentioned during his prepared remarks. That concludes my update for the quarter.

Tiff, back to you.

Tiffany Hamilton -- Head of Corporate Communications

Thanks, Jess. We'll now open the call for questions. Operator?

Questions & Answers:

Operator

[Operator instructions] Our first question will come from the line of Uy Ear with Mizuho Securities. Please go ahead.

Uy Ear -- Mizuho Securities -- Analyst

Hi, guys. Thanks for taking my question. I was wondering if you could sort of speak a little bit about your -- some more about the COVID program, particularly with COVAXIN. Could you sort of just help us understand where -- how it fits currently, I guess, within the, you know, changing landscape where the FDA, I guess, are moving forward with recommendations for bivalent and as well as companies, you know, developing, as you guys are also with the 200 series, in combination with the flu vaccine? That's my first question.

And I guess my second question is on OCU400, could you sort of help us understand, you know, as you -- what should we expect, I guess, from the phase 2 readout in midyear? And how would that help you to move into phase 3 in terms of, I guess, trial designs, as well as, you know, what sort of primary endpoint you would propose to the FDA? Thanks.

Shankar Musunuri -- Chairman and Chief Executive Officer

Thank you. Starting with the COVAXIN, first question to address, yeah, the market landscape is moving, obviously. And we -- as we stated before, we're anticipating the full data analysis by midyear. And obviously, COVAXIN is a good vaccine.

I mean, this has got solid data. It is given to a few hundred million people across the globe, it has favorable safety profile. And unfortunately, in U.S., we needed to do more work to bridge with U.S. demographic and population as stated by FDA.

So, the first trial obviously included immuno-bridging trials. That's what we're completing. And the second one, obviously, we are anticipating a safety trial because we need to bridge immuno-bridge to efficacy, the large efficacy trial done over by partners in India. And the second step is, of course, the safety bridge.

And as we stated earlier, you know, we needed to work with government agencies. Having more vaccine options is important in this -- especially with a favorable safety profile, we confirmed in our immuno-bridging trial that we didn't have any myocardiac, pericarditis, or thromboses, any of the adverse events like you see with other vaccines. And again, consistently confirming the safety data generated by our partners elsewhere. So, we believe this has a space provided we do get some help and funding from the government.

So, that's where the COVAXIN is. I mean, as I stated before, there's more work to be done. Obviously, there's a need for multiple tools in the toolkit. COVID is not done.

It will be there for many years. And we believe, with a favorable safety profile, vaccine, which is built on a traditional vaccine platform, such as polio and other vaccines, this could be a vaccine in a toolkit which could be beneficial for many patients or many subjects. Now, coming to OCU400, obviously, the landscape is changing. That's why we're in our OCU500 series, as you stated, with inhalation vaccine, the potential to control transmission and durability.

There are two things which are issues to the current vaccines. And we believe the market is going to move it into annual boosters. As we stated, there's a large market size for flu. You know, 50% of Americans are taking flu shots every year.

So, ideally, if we can combine, you know, with our technology we have, which is unique and chat platform and designing novel flu, as well as COVID, and also a combination of vaccine for a long term as Ocugen contributed to that space for public health perspective. Now, changing gears, coming to OCU400 question, as we said to you, we're monitoring multiple observational endpoints as a part of this efficacy analysis. And what we are anticipating is we have multiple things we're looking at from a structural perspective, as well as functional endpoints. Our goal is to identify, you know, one endpoint.

I mean, ideally, , you know, the same endpoint works for, you know, multiple mutations is good. But again, the data is going to tell that. And so, we have to wait until we have the data. Our goal is to identify an appropriate endpoint based on the data from this phase 2 clinical trial and then propose that endpoint with FDA and, eventually, EMA and finalize our phase 3 design, and then move on to phase 3 clinical trial.

And your question about the phase 3 clinical design, it will be pretty similar to the product which got approved in the U.S. several years ago, a nice space on gene therapy products. So, the design will be similar to that.

Uy Ear -- Mizuho Securities -- Analyst

OK. Thank you.

Operator

Your next question comes from the line of Jennifer Kim with Cantor Fitzgerald. Please go ahead.

Jen Kim -- Cantor Fitzgerald -- Analyst

Hi. Good morning. Thanks so much for taking my questions. I have a few here.

I guess the first one is OCU200. I saw that you're going to get the phase 1 started up, and we're going to see some initial data in the fourth quarter. And I'm wondering what should -- what are you looking for in that preliminary data? And how should we think about the design of that trial? And then, second, I think you mentioned that your runway gets you to the first quarter of 2024. I'm wondering how do you think about -- I think, previously, it was runway into the end of this year.

And I'm wondering, I guess, where -- how should we think about like how you're managing cash as you're balancing all these programs and how you're able to extend that.

Shankar Musunuri -- Chairman and Chief Executive Officer

Yes. OCU200, as we announced, it's a dose escalation study in a small population. Our goal is to look at the range of doses so we can pick one before we go into phase 2. So, as a part of that, I mean, obviously, we're going to look at CST, central subfield thickness, as other companies have looked at from DME space specifically.

Once again, the primary objective of any phase 1 clinical trial is safety as a part of the dose escalation to finalize the dose. And we'll be looking at observational endpoints, and one of them is CST. And now, the second question, extending runway into Q1. I'll let Jess answer that.

Jess Crespo -- Chief Accounting Officer and Senior Vice President of Finance

Sure. Hi, Jennifer. So, in terms of the extension of our runway into the first quarter, we did utilize our ATM a bit, so that has helped us extend our runway into Q1 of 2024. But as Shankar mentioned, I mean we will need to raise capital in order to progress on all of our programs.

And we're exploring many different options, including our focus on nondilutive funding, as we stated.

Jen Kim -- Cantor Fitzgerald -- Analyst

OK, great. And maybe if I could squeeze one more question. With the two additional IND filings in the second quarter of this year, should we think about you -- or initiation of those clinical programs, could that come this year? Or are you thinking more in, I guess, early next year?

Shankar Musunuri -- Chairman and Chief Executive Officer

As we stated -- yeah, yeah. Again, I just wanted to confirm. The 410 and 410ST, we call it, we separated it out because 410 targets dry age-related macular degeneration. Specifically, we'll be targeting late-stage patients in geographic atrophy, and that's targeted for filing in second quarter of this year.

Similarly, our ARCU410ST targeting orphan disease, Stargardt, is also targeted for second quarter of this year IND filing.

Jen Kim -- Cantor Fitzgerald -- Analyst

OK.

Operator

Your next question will come from the line of Jonathan Aschoff with ROTH MKM. Please go ahead.

Jonathan Aschoff -- ROTH Capital Partners -- Analyst

Thank you. Most have been answered, but did you say the NeoCart trial would start in the fourth quarter of next year, or just some time next year?

Shankar Musunuri -- Chairman and Chief Executive Officer

No. Actually, we stated the NeoCart clinical trial will start first half of next year. We are constructing cGMP manufacturing facility, and that will be complete by the end of this year.

Jonathan Aschoff -- ROTH Capital Partners -- Analyst

OK. And can you give us a little more clarity on how much is left on the ATM as of today?

Jess Crespo -- Chief Accounting Officer and Senior Vice President of Finance

Yeah. So, as part of our, I would say, general corporate housekeeping, we've canceled the ATM in connection with converting our automatic shelf into a regular shelf. So, you'll see those filings come through today. So, we'll put the ATM back up when and if it's appropriate for the appropriate amount.

So, at this point, it's in capital.

Jonathan Aschoff -- ROTH Capital Partners -- Analyst

OK. But can you tell us how much of that ATM was actually used overall from the core and in it?

Jess Crespo -- Chief Accounting Officer and Senior Vice President of Finance

Sure. Yes. Under that ATM, we've sold approximately $14 million in terms of gross proceeds, and we've netted about $13.6 million.

Jonathan Aschoff -- ROTH Capital Partners -- Analyst

Yes. Thank you very much. That is all.

Jess Crespo -- Chief Accounting Officer and Senior Vice President of Finance

You're welcome.

Operator

Your next question comes from the line of Robert LeBoyer with Noble Capital Markets. Please go ahead.

Robert LeBoyer -- Noble Capital Markets -- Analyst

Good morning. Thank you for laying out some of the milestones for the COVAXIN programs. Could you give any time frames for -- well, you had mentioned the midyear top line or conclusions in full data. Could you give some of the timeframes for the phase 3 and some of the other program starts and milestones?

Shankar Musunuri -- Chairman and Chief Executive Officer

Robert, good morning. Are you specifically referring to COVAXIN or other programs?

Robert LeBoyer -- Noble Capital Markets -- Analyst

Excuse me?

Shankar Musunuri -- Chairman and Chief Executive Officer

Are you referring to COVAXIN and other programs?

Robert LeBoyer -- Noble Capital Markets -- Analyst

Yes.

Shankar Musunuri -- Chairman and Chief Executive Officer

OK. Yeah, as I stated before, yeah, the COVAXIN, we are finishing up the current study, and we'll have the final data analysis expecting midyear this year. And as I stated before, we may need to do a safety clinical trial. We're still waiting for FDA to respond, their comments on our safety protocol.

And once we get that, obviously, we -- as we stated, we are seeking government funds to conduct the clinical trial. So, as far as other phase 3 clinical trials are concerned, there are 2 more we talked about during this earnings call. One of them is our signature OCU400 modified gene therapy platform, where we have completed recruitment in our retinitis pigmentosa portion of the phase 1/2 clinical trial. And so, based on data read, we're anticipating midyear on efficacy signal.

And we're going to get into -- planning to get into phase 3 by the end of this year for OCU400 gene therapy phase 3 clinical trial. And the second phase 3 clinical trial is related to NeoCart, our cell therapy platform, and the rate limiting for that is -- it's ophthalmic cell therapy. It's almost like a personalized medicine. So, we are building our own manufacturing facilities, renovating the existing facilities to convert them into cGMP manufacturing for cell therapy production.

And we're anticipating that construction will be complete by the end of the year. And that will allow us to initiate phase 3 clinical trial in the first half of 2024.

Robert LeBoyer -- Noble Capital Markets -- Analyst

OK. Thank you very much.

Operator

Your next question will come from the line of Sean Lee with H.C. Wainwright. Please go ahead.

Sean Lee -- H.C. Wainwright and Company -- Analyst

Good morning, guys. Just a quick question from me. So, for the proposed NeoCart study, have you finalized on the endpoint in the study design yet?

Shankar Musunuri -- Chairman and Chief Executive Officer

Yeah. I think the study design, as we agreed with FDA, includes chondroplasty as a control, and that's different than prior control they used in the prior studies. The second thing is the endpoints will include pain and function.

Sean Lee -- H.C. Wainwright and Company -- Analyst

Compared to the previous phase 3 that Histogenics ran NeoCart, what would be the key differences?

Shankar Musunuri -- Chairman and Chief Executive Officer

The key differences are -- they had a microfracture control, which is -- I mean, so what we did is we looked into the current standard of care, which is chondroplasty. And so, based on that, we actually wanted to use chondroplasty, and FDA agreed to that. The second thing is we're also going to restrict the lesion size to three centimeter square and really focus on that so that, you know, it's not very broad like they did before. So, I think with these changes, we anticipate we'll have better prospects of relatively easily recruiting patients.

That's important because chondroplasty is standard of care, not microfracture. And that's really important. That's an important change. And also, focusing on a specific range for lesion size is very important for us.

Sean Lee -- H.C. Wainwright and Company -- Analyst

Great. One last final follow-up on that. For the new manufacturing facility that you're building, would that be only for supporting materials for the phase 3? Or could you scale that up to potential commercial later as well?

Shankar Musunuri -- Chairman and Chief Executive Officer

Good questions, Sean. When we build this personalized medicine, many cell therapies, this is like a scale out, not scale up. So, these are very small -- you know, you can call them bioreactors, we call them tissue-engineering process units, TEP, you know. So, these things are very small suites.

So, this can be used for commercial manufacturing, too.

Sean Lee -- H.C. Wainwright and Company -- Analyst

I see. Thanks for that. That's all the questions I have.

Operator

Your next question will come from the line of Daniil Gataulin with Chardan. Please go ahead.

Daniil Gataulin -- Chardan -- Analyst

Hey. Good morning, guys. Thank you for taking the question, and congrats on all the progress. Just a couple of follow-ups, one on the cash runway in terms of bundling.

Are you expecting to fund the OCU500 series vaccine programs internally or look for external funding? That's one. And two, in relation to 410 and 410ST, the two INDs that you plan to file this year, are you planning to initiate the actual trials this year as well, or are you planning to initiate those in 2024? Thanks.

Shankar Musunuri -- Chairman and Chief Executive Officer

Good morning. The first one is related to OCU500 series inhalation vaccines. So, as we stated before, we are funding the development of those vaccines and taking it to the clinic. So, we're also in parallel working with various government agencies.

Because of the need, we believe -- you know, we are trying to secure funding from them. So, we do need their support to move them into the clinic. But the development part and preclinical studies, we have budget for it, and we're going to complete that. And the second question you had on OCU410 and OCU410ST targeting dry AMD and Stargardt disease, those INDs are scheduled to be filed, planning in the second quarter of this year.

And as soon as we get a positive mark from FDA, we will start dosing patients this year.

Daniil Gataulin -- Chardan -- Analyst

OK. Thank you very much.

Operator

This concludes the Q&A portion. I will now turn the call back over to chairman and CEO, Dr. Shankar Musunuri.

Shankar Musunuri -- Chairman and Chief Executive Officer

Thank you, operator. I'd like to conclude the call with some additional remarks. I think it's clear that we are staying true to our mission as an integrated patient-centric biotechnology company that targets unmet medical needs. We believe we are in a position of strength, and we are poised to execute our goals with our pipeline for the course of 2023.

We look forward to keeping you updated on our programs throughout the year. Thanks for your time today, and have a great week.

Jess Crespo -- Chief Accounting Officer and Senior Vice President of Finance

Thanks, everyone. Have a great day.

Operator

[Operator signoff]

Duration: 0 minutes

Call participants:

Tiffany Hamilton -- Head of Corporate Communications

Shankar Musunuri -- Chairman and Chief Executive Officer

Jess Crespo -- Chief Accounting Officer and Senior Vice President of Finance

Uy Ear -- Mizuho Securities -- Analyst

Jen Kim -- Cantor Fitzgerald -- Analyst

Jonathan Aschoff -- ROTH Capital Partners -- Analyst

Robert LeBoyer -- Noble Capital Markets -- Analyst

Sean Lee -- H.C. Wainwright and Company -- Analyst

Daniil Gataulin -- Chardan -- Analyst

More OCGN analysis

All earnings call transcripts